Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Mol Cancer Ther. 2011 Dec 21;11(2):288–297. doi: 10.1158/1535-7163.MCT-11-0490

Figure 6. Oral delivery of METi significantly inhibits the in vivo growth of human medulloblastoma xenografts.

Figure 6

Human medulloblastoma xenografts were generated by flank implantation of 2×106 HGF-DAOY cells in immunodeficient mice. Five days post-tumor implantation, the animals were treated with METi by oral gavage (30 mg/kg body weight) once per day, for 3 weeks. The control group was treated with equal volume of sterile distilled water. At the end of the treatment, animals were sacrificed and tumor size was assessed by measuring tumor volume. The results show that METi treatment significantly inhibits in vivo medulloblastoma growth (p<0.01).